One new concept that emerged from these mechanistic studies was the idea that small molecules could be developed that act as inverse agonists or antagonists against, e.g. antibody driven TSH receptor activation in Graves’ disease and ophthalmopathy [21, 22]. This evidence concerns the gene TSHR and Graves disease.